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Abstract The purpose of this overview is to discuss the
changes in the 2008 WHO classification of myeloid
neoplasms, with exclusion of acute myeloid leukaemia.
Specific mutations or rearrangements leading to constitutive
activation of growth factor receptors or cytoplasmic
tyrosine kinases are now recognised as recurrent genetic
events characterising the group of myeloproliferative neo-
plasms (MPN). A newly introduced subgroup consists of
patients with persistent eosinophilia and myeloid or
lymphoid proliferations harbouring specific genetic changes
involving platelet-derived growth factor receptors alpha and
beta (PDGFRA and PDGFRB) or fibroblast growth factor
receptor 1 (FGFR1). The clinical relevance of recognising
myeloid neoplasms with aberrant tyrosine kinase activity is
based in novel treatment options with tyrosine kinase
inhibitors. The myelodysplastic syndromes (MDS) without
increased blasts are further divided into subtypes of
refractory cytopaenias with unilineage dysplasia. A new
provisional entity is refractory cytopaenia of childhood.
Down syndrome- and therapy-related myeloid neoplasms,
including MDS, were moved to the section of acute
myeloid leukaemia and related precursor neoplasms.
Keywords Review.Classification.Myelodysplastic
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Introduction
Since the publication of the third edition of the WHO
classification in 2001 several fundamental changes in the
understanding of myeloid neoplasms have occurred. The
conceptual change in classifying myeloid disorders, from a
morphology-based to an integrative approach with strong
emphasis on recurrent cytogenetic and molecular aberra-
tions, which was initiated for the acute leukaemias in the
2001 WHO classification, now extends to many of the
chronic myeloproliferative disorders. The discovery of
activating point mutations in tyrosine kinases, starting with
JAK2 V617F in Ph- myeloproliferative neoplasms, especially
polycythemia vera, led to a unifying concept of growth
receptortyrosinekinaseactivationinvolvedintheaetiologyof
myeloproliferative neoplasms (MPN). This explains the
inclusion of mastocytosis in the group of MPN in the updated
WHO classification [1].
A new category in the 2008 classification is the group of
patients with unexplained persistent eosinophilia, previously
grouped as hypereosinophilic syndrome or chronic eosino-
philic leukaemia. In most of these patients, specific genetic
changes involving platelet-derived growth factor receptor
alpha (PDGFRA),platelet-derivedgrowthfactorreceptorbeta
(PDGFRB) or fibroblast growth factor receptor (FGFR1) can
be demonstrated. This group is now defined by the genetic
aberration, in combination with its clinical presentation with
myeloidorrarely,lymphoidproliferations.Thiscategorization
reduces the spectrum of myelodysplastic/myeloproliferative
neoplasm (MDS/MPN) overlap diseases, since a subset of
cases of chronic myelomonocytic leukaemia (CMML), but
also some cases of atypical chronic myelogenous leukaemia
(aCML) and juvenile myelomonocytic leukaemia (JMML)
now can be assigned to this new group. The rationale for
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from other myeloid neoplasms lies again in the new treatment
options with tyrosine kinase inhibitors.
In the previous WHO classification of myelodysplastic
syndromes (MDS) a significant number of patients could
not be classified because they did not fulfil the minimum
requirements of at least bilineage dysplasia and cytopaenia,
if the erythroid lineage was not affected. For these cases,
subtypes of refractory cytopaenias with unilineage dysplasia
werenowintroduced.Furthermore,thediagnosisofrefractory
cytopaenia with multilineage dysplasia (RCMD) required at
least bicytopaenia and a two-lineage dysplasia. In the new
classification, a single cytopaenia in combination with a
bilineage dysplasia is sufficient for this diagnosis. The
distinction of RCMD with or without ring sideroblasts is no
longer incorporated in the 2008 classification. A newly
introduced provisional entity is refractory cytopaenia of
childhoodforalljuvenileMDScaseswithoutincreasedblasts.
The additional diagnostic and prognostic value of bone
marrow biopsies, especially for BCR-ABL negative MPN
and MDS is acknowledged in the updated WHO classifi-
cation and a semi-quantitative grading of fibrosis is
proposed. Flow-cytometric immunophenotyping is not yet
recognised as an obligatory diagnostic tool for any of the
myeloid neoplasms.
In this review, the changes in definition of the myeloid
neoplasms with myeloproliverative and/or dysplastic fea-
tures, with the exception of acute myeloid leukaemia will
be presented.
Myeloproliferative neoplasms
The group of the chronic myeloproliferative diseases, now
called myeloproliferative neoplasms (MPN), is extended by
the inclusion of mastocytosis (see Table 1). The diagnostic
criteria are unchanged for chronic myelogenous leukaemia
(CML), BCR-ABL1-positive, chronic neutrophilic leukae-
mia (CNL) and myeloproliferative neoplasm, unclassifiable
(MPN, U). All other disease entities underwent major or
minor revisions, mainly due to new genetic insights
enabling more strict disease definition. The most significant
impact on the classification of MPN was the discovery of
the activating point mutation V617F in the pseudokinase
domain of the janus kinase 2 (JAK2) which leads to
independence from exogenous hematopoietic growth fac-
tors due to constitutive signalling in the JAK-STAT
pathway, and results in overproduction of mature blood
cells, so characteristic for MPN. However, it has to be taken
into account that the absence of a JAK2 mutation does not
exclude a diagnosis of either PMF or ET, and that in the
presence of the mutation, a proper disease categorization
still requires a haematological work-up including a trephine
BM biopsy. Nevertheless, inclusion of the JAK2 V617F
mutation (or JAK2 exon 12 mutations in PV) into the
diagnostic criteria of MPN has simplified diagnosis for
cases with borderline hematologic changes which previously
required extensive work to exclude a reactive increase in
peripheral blood cell counts.
Chronic eosinophilic leukaemia
In the new WHO classification chronic eosinophilic
leukaemia (CEL), not otherwise specified, is a limited
group of cases with a clonal proliferation of eosinophil
precursors resulting in persistent eosinophilia as dominant
hematologic abnormality, in which no specific genetic gene
rearrangement including BCR-ABL1, PDGFRA, PDGFRB
or FGFR1 is present. Cases with a PCM1-JAK2 rearrange-
ment, previously called atypical CML, are suggested to be
included in this category. The clinical and morphological
criteria were not changed. For cases without demonstration
of clonality, idiopathic hypereosinophilic syndrome remains
the main differential diagnosis.
Polycythaemia vera
Polycythaemia vera (PV) now only requires the presence of
the JAK2 V617F mutation or an equivalent mutation in
exon 12, in addition to increased haemoglobin (>18.5 g/dL
in men, 16.5 g/dL in women) and either panmyelosis in a
Table 1 Myeloproliferative neoplasms, new names and changed
criteria
WHO 2008 WHO 2001
Chronic myelogenous leukaemia,
BCR-ABL-1 positive
Chronic myelogenous
leukaemia
Chronic neutrophilic leukaemia Unchanged
Polycythaemia vera Unchanged
- JAK2 V617F or exon 12 mutation
Primary myelofibrosis Chronic idiopathic
myelofibrosis
- JAK2 (50%) or MPL (5%) mutation
Essential thrombocythaemia Unchanged
- Thrombocytes >450×10
9/L - Thrombocytes
>600×10
9/L
- JAK2 mutation (50-60%)
Chronic eosinophilic leukaemia, NOS Chronic eosinophilic
leukaemia
- No BCR-ABL1, PDGFRA, PDGFRB
or FGFR1 translocation
Mastocytosis not included in this
category before
- KIT mutation (>90 %)
Myeloproliferative neoplasm,
unclassifiable
Chronic myeloproliferative
disease, unclassifiable
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endogenous erythroid colony formation [2]. This allows an
earlier diagnosis, often before the onset of obvious
splenomegaly or leukocytosis, and obviates red blood cell
mass measurement. In addition, the description of a pre-
polycythaemic phase with thrombocytosis that occurs in up
to 15% of the patients and clinically mimics ET is added. A
bone marrow trephine should be performed mainly for
grading of fibrosis.
Primary myelofibrosis
In the revised classification, the diagnostic criteria of
primary myelofibrosis (PMF) are independent of disease
stage and the presence of fibrosis at diagnosis. They include
now detection of a JAK2 V617F (approx. 50%) or MPL
(5%) mutation, which obviates extensive exclusion of
reactive causes of fibrosis. A semi-quantitative grading of
bone marrow fibrosis ranging from MF-0 (normal) to MF-3
(osteosclerosis) is adopted [3].
Essential thrombocythaemia
Although the diagnosis of essential thrombocythaemia (ET)
still requires exclusion of all other causes of sustained
thrombocytosis, the diagnostic platelet count level is lowered
from 600 to 450×10
9/L and a JAK2 or MPL mutation, if
present (JAK2 in about 50%), now can serve as a positive
criterion. For the rare event of post-ET myelofibrosis,
diagnostic criteria are given, intending to help distinguish
post-ET myelofibrosis from PMF. Whether also pre-fibrotic
PMF, which shows a worse prognosis in studies based on
WHO criteria, and ET can be safely distinguished on
morphological grounds remains a matter of debate.
Mastocytosis
Mastocytosis was previously considered a haematopoietic
disorder that was not grouped under the myeloproliferative
disorders, since its clonal, neoplastic nature could usually
not been proven. Due to the recognition of activating point
mutations in the KIT gene, typically D816V, it is now
grouped under the MPN. The diagnostic criteria were not
changed, and all provisional entities, consisting of bone
marrow mastocytosis and smouldering systemic mastocy-
tosis as subtypes of indolent systemic mastocytosis (SM),
lymphadenopathic mastocytosis with eosinophilia (if
PDGFRA rearrangement is excluded) as part of aggressive
mastocytosis, and SM with associated clonal haematolog-
ical non-mast-cell lineage disease (SM-AHNMD), are now
accepted as definitive variants. Of clinical importance is the
resistance of the KIT D816V mutation to the kinase
inhibitor imatinib.
Myeloid and lymphoid neoplasms with eosinophilia
and abnormalities of PDGFRA, PDGFRB or FGFR1
A completely new group of diseases, defined by their shared
genetic defect, leading to an aberrant expression of PDGFRA,
PDGFRB or FGFR1, was compiled from former categories
of myeloid neoplasms and lymphoid neoplasms with features
of MPN (Table 2). These are all rare diseases, usually
presenting with eosinophilia and variable clinical features that
are influenced by the partner gene of the rearranged growth
factor receptor. Since the cell of origin is a mutated multi- or
pluripotent stem cell, the involved cell lineage can range from
myeloid to lymphoid or mast cells and combinations of these.
These neoplasms are sensitive to tyrosine kinase inhibitors.
Acute transformations are usually of the myeloid lineage.
Myeloid and lymphoid neoplasms with PDGFRA
rearrangement
Neoplasms with PDGFRA rearrangement present in most
cases as a chronic eosinophilic leukaemia with a cryptic
deletion at 4q12 (including the CHIC2 gene) that leads to a
FIP1L1-PDGFRA fusion gene. Splenomegaly, increased
serum tryptase and a marked elevation of serum vitamin
B12 are common, and trephine biopsies can show an
increase of sometimes atypical mast cells. Because of these
features, such cases previously had commonly been
diagnosed as systemic mastocytosis with eosinophilia; a
term now obsolete due to the molecular alterations
separating these two entities. In rare cases, primary
presentation as or progression to acute myeloid leukaemia
or T-lymphoblastic lymphoma is seen.
Myeloid neoplasms with PDGFRB rearrangement
Chronic myelomonocytic leukaemia with eosinophilia and
t(5;12) involving the ETV6 gene is the most common
presentation of myeloid neoplasms with PDGFRB rear-
rangement. Variant partner genes can induce clinical
pictures of chronic eosinophilic leukaemia, atypical CML
or JMML, usually with eosinophilia.
Myeloid and lymphoid neoplasms with FGFR1 abnormalities
The myeloid and lymphoid neoplasms with FGFR1
abnormalities also known as “8p11 stem cell syndrome”
Table 2 Myeloid and lymphoid neoplasms with eosinophilia and
abnormalities of PDGFRA, PDGFRB or FGFR1
Myeloid and lymphoid neoplasms with PDGFRA rearrangement
Myeloid neoplasms with PDGFRB rearrangement
Myeloid and lymphoid neoplasms with FGFR1 abnormalities
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terised by a somewhat younger age of onset (around
32 years) and a more variable clinical picture than the
other neoplasms in this category. Presentation may be as
CEL, AML, lymphoblastic lymphoma or myeloid sarcoma
with extramedullary and nodal involvement. Systemic
symptoms and peripheral or tissue eosinophilia are com-
mon. The WHO classification recommends adding a
specification, including information of the major involved
cell line in the diagnosis, for example leukaemia/lymphoma
associated with FGFR1 rearrangement/myeloid sarcoma.
Myelodysplastic/myeloproliferative neoplasm
Theunifyingbiologicaldefectinthegroupofmyelodysplastic/
myeloproliferative neoplasms (Table 3) seems to be an
aberrancy in the RAS/MAPK signalling pathway, leading to
neutrophilic proliferations due to GM-CSF hypersensitivity.
However, data are still insufficient for diagnostic or prog-
nostic purposes and the definition of this group remains
largely unchanged, except for cases with specific recurrent
genetic defects mentioned above that are moved to other
categories. The definitions of JMML and myelodysplastic/
myeloproliferative neoplasm, unclassifiable (MDS/MPN, U)
have not been changed.
Chronic myelomonocytic leukaemia
The definition of CMML is only slightly changed by
excluding cases with PDGFRA or PDGFRB rearrangement,
also resulting in omission of the subgroup CMML with
eosinophilia. JAK2 V617F occurs in a minority (<5%) of
otherwise typical cases. The categorization of CMML into
two prognostic groups is based on blast counts, with <5%
blasts and promonocytes in the PB and <10% in the bone
marrow for CMML-1, and 5–19% blasts and promonocytes
in the PB and 10–19% in the bone marrow for CMML-2.
Atypical chronic myelogenous leukaemia, BCR-ABL-1
negative
The addition of “BCR-ABL-1 negative” in the updated
WHO classification reflects the somewhat stricter definition
of atypical chronic myelogenous leukaemia, BCR-ABL-1
negative (aCML), as a proliferation of the neutrophil
lineage with exclusion of BCR-ABL-1, PDGFR and FGFR
translocations and prominent signs of dysplasia, especially
dysgranulopoiesis. Although the JAK2 V617F mutation is
still allowed according to the WHO classification, recent
results demonstrate that aCML as based on the morpholog-
ical criteria of the WHO is a JAK2 V617F negative
neoplasm [4]. Cases with PCM1-JAK2 translocation are
considered as probable CEL.
Refractory anaemia with ring sideroblasts associated
with marked thrombocytosis
Although more cases of refractory anaemia with ring
sideroblasts associated with marked thrombocytosis
(RARS-T) have been studied since it was accepted as a
provisional entity in 2001, its status is not yet determined.
Whether these cases are really a unique entity or represent
secondary changes in either MDS or MPN is not yet clear.
Detection of the JAK2 V617F mutation in about 60% of
cases puts them closer to the MPN category. In a recent
compilation of clinical, morphological and molecular data
from the literature, the authors convincingly argue that
RARS-T might indeed be a variant of ET [5].
Myelodysplastic syndromes
Myelodysplastic syndromes are characterised by varying
combinations of cytopaenias, dysplastic morphology of the
myeloid cell lines and cytogenetic aberrancies. Since the
third edition that extended a mainly morphological classi-
fication by incorporating cytogenetic information for
diagnosis (for example MDS with isolated del(5q)) and
risk stratification, the biological spectrum of MDS is now
more fully acknowledged by adding a new category of
refractory cytopaenias with unilineage dysplasia and bi- or
unilineage cytopaenia (Table 4).
Even in the absence of dysplasia above the 10%
threshold, persistent cytopaenia can now be diagnosed as
MDS, U in the presence of specific cytogenetic abnormal-
ities that include frequent chromosomal losses and trans-
locations. For persistent cytopaenia without cytogenetic
changes or dysplasia, the use of ‘idiopathic cytopaenia of
undetermined significance (ICUS)’ is recommended. In any
case, exclusion of reactive conditions, for example drug or
toxin exposure, infections, immunological disorders or
vitamin deficiencies remains essential.
Myeloid proliferations related to Down syndrome and
therapy-related myeloid neoplasms, including MDS, are
now included in the group of acute myeloid leukaemia and
Chronic myelomonocytic leukaemia
Atypical chronic myelogenous leukaemia, BCR-ABL-1 negative
Juvenile myelomonocytic leukaemia
Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (provisional)
Table 3 Myelodysplastic/
Myeloproliferative neoplasms
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this review.
Refractory cytopaenia with unilineage dysplasia
The new category of refractory cytopaenia with unilineage
dysplasia (RCUD) includes uni- or bicytopaenias with
dysplasia in more than 10% of cells of only one lineage in
the absence of increased blasts (<1% in blood, <5% in bone
marrow). The dysplastic lineage defines the name. Thus, in
refractory anaemia the criteria are slightly altered to allow
other cytopaeniasinadditiontoanaemia,aslongasthereisno
dysplasia in more than 10% of these other cell lines.
Refractory neutropenia and refractory thrombocytopaenia
are new additions with dysplasia in at least 10% of
neutrophils or megakaryocytes, respectively. Cases with
pancytopaenia and unilineage dysplasia have to be classified
as MDS, U. An overview of the classification of MDS
without an increase in marrow blasts is given in Table 5.
Refractory anaemia with ring sideroblasts
The criteria of refractory anaemia with ring sideroblasts
have not been changed, except for allowing bicytopaenia.
Refractory cytopaenia with multilineage dysplasia
Two changes were introduced for refractory cytopaenia
with multilineage dysplasia. First, while at least two cell
lines have to be dysplastic, the number of cytopaenias is
now irrelevant provided there is at least one cytopaenia.
Second, the occurrence of >15% ring sideroblasts does
no longer require separate mentioning as RCMD-RS
since prognosis and other disease characteristics are not
different.
Refractory anaemia with excess blasts
The definition of both categories of refractory anaemia with
excess blasts, RAEB-1 and RAEB-2 was not changed, but
Auer rods are now considered a definite criterion for
RAEB-2, irrespective of the blast percentage.
Hypoplastic MDS and MDS with myelofibrosis are
separately discussed since they pose specific problems to
diagnose correctly. They are not recognised as defined
entities because of lack of significant prognostic impact.
Diagnosis usually requires bone marrow biopsy for estima-
tion of blasts, CD34 stain can be especially helpful in this.
A temporary definition for RAEB with fibrosis (RAEB-F),
in case of more than 5% blasts in the BM combined with
diffuse coarse reticulin fibrosis, is proposed to be able to
assess the prognostic impact of fibrosis in future. Usually,
an increase of highly dysplastic and often small mega-
karyocytes is present, making histological distinction from
acute panmyelosis with myelofibrosis, with its abrupt clinical
onset, and acute megakaryoblastic leukaemia difficult.
Myelodysplastic syndrome with isolated del(5q)
The myelodysplastic syndrome with isolated del(5q) is
somewhat more strictly defined by including an obligatory
blast count <1% in the peripheral blood and absence of
Auer rods. Loss of chromosome Y and JAK2 V617F
mutation, but no other genetic aberrancies are allowed until
more data are available. Since also some patients with
additional chromosomal aberrancies, dysplasia of the
myeloid lineage or increased blasts seem to benefit from
lenalidomide treatment [6], some changes in the genetic
definition of this category can be expected in the future.
Table 4 Myelodysplastic syndromes
Refractory cytopaenia with unilineage dysplasia
Refractory anaemia with ring sideroblasts
Refractory cytopaenia with multilineage dysplasia
Refractory anaemia with excess blasts
Myelodysplastic syndrome with isolated del(5q)
Myelodysplastic syndrome, unclassifiable
Refractory cytopaenia of childhood
Table 5 Summary of cytopaenias and dysplasia characteristics in MDS without an increase of marrow blasts
Dysplasia Cytopenia(s) ring sideroblasts Categories
Unilineage Uni-or bicytopenia <15% Refractory cytopenia with unilineage dysplasia (RCUD) including:
- Refractory anaemia (RA)
- Refractory neutropenia (RN)
- Refractory thrombocytopenia (RT)
Pancytopenia Myelodysplastic syndrome, unclassified (MDS-U)
Uni-or bi- or pancytopenia >15% Refractory anaemia with ring sideroblasts (RARS)
Multilineage (at least 2) Uni-or bi- or pancytopenia <15% / >15% Refractory cytopenia with multilineage dysplasia (RCMD)
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In the prior WHO classification, myelodysplastic syndrome,
unclassifiable (MDS, U) has been an ill-defined wastebasket
ofcaseswithoutincreasedblaststhatdidnotfulfiltherequired
criteria. In the new definition, this diagnosis can be made in
patients with all characteristics of RCUD or RCMD, but a
slightly higher percentage of blasts in the peripheral blood
(1%). Cases with pancytopaenia and unilineage dysplasia
have also to be classified as MDS, U.
Finally, persistent cytopaenia in the presence of specific
cytogenetic abnormalities but in the absence of dysplasia
above the 10% threshold is diagnosed as MDS, U. A more
specific classification is recommended whenever this
becomes possible during the development of the disease.
Childhood myelodysplastic syndrome
An entirely new addition to the classification is the
definition of childhood MDS (without specifying the age
limit). In cases with increased blasts (2–19% in PB or 5–
19% in BM) the same criteria for RAEB-1 and RAEB-2 are
suggested as for adults. Because of some specific disease
characteristics of MDS without increased blasts in children,
and due to uncertainty about the significance of the number
of cytopaenias or dysplastic cell lines, one provisional
entity ‘refractory cytopaenia of childhood (RCC)’ is
proposed to cover all these remaining cases. In contrast to
adult MDS, a hypocellular BM and bi- or pancytopaenia are
common in children. Often erythropoiesis is prominent with
large islands of immature forms and impaired maturation.
Bone marrow biopsy is also very helpful in identifying
dysplastic changes in the often sparse megakaryopoiesis.
As in adults, dysplasia is required to be present in at least
10% of cells in one cell line. The clinical and morpholog-
ical distinction between RCC and inherited BM failure
syndromes and aplastic anaemia remains difficult and
controversial for the hypocellular cases.
All myeloid proliferations related to Down syndrome,
including MDS, are considered a unique entity and now
grouped with acute myeloid leukaemia and related precursor
neoplasms.
Conclusions
The updated, fourth edition of the WHO classification
reflects the increased knowledge about genetic alterations
in myeloproliferative neoplasms and gives a more coherent
and systematic classification of myelodysplastic syn-
dromes. Most importantly, we see that this increased
understanding of the biologic basis of these disorders
translates into therapeutic advances benefitting the patients.
Nevertheless, classification of myeloid disorders still
requires a multi-faceted rather than a unidirectional ap-
proach, including a meticulous clinical and morphological
work-up in addition to genetic analysis.
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